Valuation BriaCell Therapeutics Corp. Nasdaq
Stocks
BCTX
CA1079303071
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
16:00:00 2026-08-20 EDT
|
5-day change | 1st Jan Change | ||
| 3.930 USD | -0.76% |
|
+14.24% | -44.73% |
Company Valuation: BriaCell Therapeutics Corp.
Data adjusted to current consolidation scope
| Fiscal Period: July | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 5.148 | 78.61 | 101.5 | 106.4 | 13.63 | 12.81 |
| Change | - | 1,427.04% | 29.07% | 4.9% | -87.19% | -6.05% |
| Enterprise Value (EV) 1 | 5.429 | 21.37 | 60.42 | 85.18 | 12.77 | -5.058 |
| Change | - | 293.6% | 182.77% | 40.98% | -85.01% | -139.6% |
| P/E | - | -54.3x | -3.77x | -5.12x | -2.56x | -0.12x |
| PBR | - | 1.37x | 9.82x | -28.2x | -5.72x | 0.77x |
| PEG | - | - | -0x | 0.2x | 0x | -0x |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -1.13x | -3.07x | -3.96x | -3.66x | -0.38x | 0.19x |
| EV / EBIT | -1.12x | -3.06x | -3.95x | -3.66x | -0.38x | 0.19x |
| EV / FCF | 21x | -3.65x | -8.81x | -5.37x | -1.18x | 0.27x |
| FCF Yield | 4.77% | -27.4% | -11.3% | -18.6% | -84.8% | 374% |
| Dividend per Share 3 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 3 | - | -14.22 | -259.8 | -195 | -43.68 | -62.19 |
| Distribution rate | - | - | - | - | - | - |
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -4.821 | -6.958 | -15.27 | -23.26 | -33.25 | -27.1 |
| EBIT 1 | -4.84 | -6.973 | -15.29 | -23.27 | -33.33 | -27.2 |
| Net income 1 | -4.944 | -0.4283 | -26.84 | -20.3 | -4.791 | -26.31 |
| Net Debt 1 | 0.2808 | -57.24 | -41.04 | -21.25 | -0.8621 | -17.87 |
| Reference price 3 | 1,069.572 | 772.222 | 980.759 | 998.928 | 111.849 | 7.298 |
| Nbr of stocks (in thousands) | 4.81 | 102 | 103 | 107 | 122 | 1,755 |
| Announcement Date | 11/30/20 | 10/28/21 | 10/27/22 | 10/25/23 | 10/29/24 | 10/15/25 |
1USD in Million2CAD in Million3USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 21.6x | 7.56x | 15.41x | 1.37% | 72.21B | |
| 36.46x | 9.42x | 28.89x | 0.04% | 63.98B | |
| -82.59x | 15.45x | -74.5x | -.--% | 28.53B | |
| 31.75x | 6.24x | 16.52x | -.--% | 25.07B | |
| -17.57x | 7.2x | -9.35x | -.--% | 28.42B | |
| 27.22x | 5.11x | 17.13x | -.--% | 20.04B | |
| 52.91x | 19.58x | 39.65x | 0.29% | 18.19B | |
| 7705.33x | 40.58x | -1416.2x | -.--% | 15.96B | |
| 16.82x | 4.99x | 11.65x | -.--% | 13.48B | |
| Average | 865.77x | 12.90x | -152.31x | 0.19% | 31.76B | |
| Weighted average by Cap. | 442.62x | 10.93x | -71.34x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- BCT Stock
- BCTX Stock
- Valuation BriaCell Therapeutics Corp.
Select your edition
All financial news and data tailored to specific country editions
